Purpose
To evaluate the clinical efficacy and safety of a Chinese single-use flexible ureteroscope (ZebraScopeTM) for the treatment of upper urinary tract calculi ≤2 cm based on a retrospective database.
Methods
Overall, 84 patients with upper urinary tract calculi who underwent FURS at our hospital from July, 2020 to January, 2021 were enrolled and reviewed. Demographic characteristics and perioperative data were evaluated and analyzed.
Results
We identified 84 patients: 51 male and 33 female. The mean age of the patients was(49.63±12.23)years, and the mean body mass index was༈24.44±3.62༉Kg/m2. The degree of hydronephrosis was absent, mild, moderate and severe in 24, 35, 21 and 4 patients, respectively. The average operation time was༈74.57±42.51༉min, and the average blood loss was༈5.28±4.99༉ml. The catheter retention time was༈1.71±0.99༉day and the double-J tube retention time was༈32.89±13.23༉day. The length of hospital stay was༈4.29±3.28༉day. The stone-free rate was 77.78% after 1-month, and the cost of hospitalization was ¥༈34619±8719.16༉. The overall complication rate was 4.76%. There were significant increase in leukocyte, neutrophils, and decrease in urea nitrogen, albumin and globulin after surgery (P༜0.05), while no significant difference were observed in hemoglobin and creatinine (P༞0.05).
Conclusion
The Chinese single-use ureteral flexible ureteroscope (ZebraScopeTM)can be considered effective and safe for the treatment of upper urinary tract calculi ≤ 2 cm.